Company Overview and News

9
3rd telco selection delayed anew

17h business.inquirer.net
The Duterte administration’s third telco initiative has stalled as the oversight committee members crafting the draft rules for the selection process appear unable to overcome big differences on how it should be implemented.
GLO GTMEY GTMEF GLOPP GLOPA

9
Globe, De La Salle–College of Saint Benilde prepare for the Future of Learning

2018-06-16 business.inquirer.net
Michelle Tapia, Head of Strategy, Innovation, and Transformation of Globe myBusiness and Brother Dennis Magbanua, FSC, President of De La Salle – College of Saint Benilde (DLS-CSB) show the MOA for a three –year research grant. Together with them are Derrick Heng, Senior Advisor for Globe myBusiness (left) and Robert Tang, DLS-CSB Chancellor (right).
GLO GTMEY GTMEF GLOPP GLOPA

13
Now Corp. inks MoU with TransCo for use of fiber assets

2018-06-14 bworldonline
NOW CORP. on Thursday announced it signed a memorandum of understanding (MoU) with the National Transmission Corp. (TransCo) for the use of the latter’s fiber and microwave assets for the establishment of a nationwide fixed broadband network.
GLO NG NOW GTMEY NGGTF GTMEF GLOPP GLOPA DNOW NGG

9
DICT orders NTC to review fees for mobile spectrum held by Globe, Smart

2018-06-14 bworldonline
THE Department of Information and Communications Technology (DICT) has ordered the National Telecommunications Commission (NTC) to review spectrum user fees for specific frequency bands to determine whether the rights holders are making efficient use of them.
GLO GTMEY GTMEF GLOPP GLOPA

14
SEC approves Now Corp.’s preferred shares offering

2018-06-13 bworldonline
THE Securities and Exchange Commission (SEC) on Wednesday gave the go-signal for Now Corp.’s proposal to issue up to P1 billion worth of preferred shares.
GLO PSKXF NOW GTMEY PHSXY PSE GTMEF GLOPP GLOPA DNOW

9
Bayan seeks quick resolution of other public cases

2018-06-13 newsinfo.inquirer.net
Bayan Muna Rep. Carlos Zarate and party chair Neri Colmenares urged the Supreme Court (SC) on Wednesday to expedite the resolution of important public interest cases, “hopefully with the same haste with which it decided on the ouster case of Chief Justice Maria Lourdes Sereno.”
GLO GTMEY GTMEF GLOPP GLOPA

9
Tougher rules in store for 3rd major telco

2018-06-10 bworldonline
GROUPS looking to vie for the distinction of becoming the Philippines’ third major telecommunications service provider likely face tougher financial and technical requirements, according to departments overseeing the process.
GLO GTMEY GTMEF GLOPP GLOPA

13
DICT looks to name third telco before yearend

2018-06-10 bworldonline
THE Department of Information and Communications Technology (DICT) said the inter-agency committee overseeing the selection of a third telco player will come up with a target timetable for the announcement of the new entrant.
GLO NG GTMEY NGGTF GTMEF GLOPP GLOPA NGG

13
Crucial telco deal signed

2018-06-08 business.inquirer.net
The government’s plan to provide high-speed and inexpensive internet to public areas around the country advanced on Friday with the signing of a crucial agreement for the use of spare fiber optic assets owned by the state.
GLO NG GTMEY NGGTF GTMEF GLOPP GLOPA NGG

9
Cell sites issue seen as major concern in Globe’s 5G rollout plan

2018-06-07 business.inquirer.net
Fifth generation or 5G wireless technology will make its commercial debut in the Philippines by the middle of next year.
GLO GTMEY GTMEF GLOPP GLOPA

9
Globe Telecom to introduce 5G next year

2018-06-07 business.inquirer.net
Fifth generation or 5G wireless technology will make its commercial debut in the Philippines by the middle of next year.
GLO GTMEY GTMEF GLOPP GLOPA

36
Stock price index up slightly in thin trade

2018-06-06 business.inquirer.net
The benchmark Philippine Stock Exchange index (PSEi) managed to close with a small gain on Wednesday, a day after inflation fears eased with the release of data for May.
GTCAP GTCXY GTMEY BDOUY BDOUF JBFCF PHSXY GTMEF PSE SPHXF SPHZF GLOPA AYAAF PSKXF AYAAY JBFCY GLOPP SMPH BDO GLO SPHXY JFC BBRRF BLOOM ALI LTG

9
Globe myBusiness, Restaurant Business Network partner for RestomaniaPH 2018

2018-06-04 business.inquirer.net
Globe myBusiness Senior Advisor Derick Heng addresses guests in his opening keynote and talks about the Globe myBusiness Restaurant Business Network, a restaurant and café- specific business ecosystem designed to provide relevant services to companies in the food industry.
GLO GTMEY GTMEF GLOPP GLOPA

9
All Disney, all the time—in one app

2018-06-02 lifestyle.inquirer.net
Filipiniana-clad Mickey and Minnie Mouse are flanked by Amrita Pandey, head of media distribution and OTT, The Walt Disney Company South Asia; Mahesh Samat, EVP and managing director The Walt Disney Company South Asia; Ernest Cu, Globe Telecom president and CEO; Albert de Larrazabal Globe chief commercial officer at the launch of DisneyLife in Glorietta. –PHOTOS BY LEO M. SABANGAN II
GLO GTMEY GTMEF GLOPP GLOPA

9
Mynt CEO Anthony Thomas receives Asian Banker Innovation Leadership Award for PH

2018-05-31 business.inquirer.net
(from left to right) : Foo Boon Ping, Managing Editor, The Asian Banker, Paul Chow – former Chief Executive of Hong Kong Exchange, Mynt President and CEO Anthony Thomas, and David Gyori, International Resource Director, The Asian Banker.
GLO GTMEY GTMEF GLOPP GLOPA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

10h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...